Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04589650 · ClinicalTrials.gov registry record · Phase 2
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
A Phase 2 study of PIK3CA-related Overgrowth Spectrum (PROS), sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT04589650 is a Phase 2 study of PIK3CA-related Overgrowth Spectrum (PROS) that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 206 participants, above the 141-participant average among 3 other PIK3CA-related Overgrowth Spectrum (PROS) trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT04589650, a Phase 2 study of PIK3CA-related Overgrowth Spectrum (PROS), is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension periods to assess the efficacy, safety and pharmacokinetics (PK) of alpelisib in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Alpelisib
Study Locations (20)
Other
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Shanghai
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Dijon
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Tours
Ohio
- Cincinnati Children s Hospital Medical Center - Cincinnati
- Cinn Children Hosp Medical Center - Cincinnati
Texas
- Unv of TX Southwestern Medical Center - Dallas
- Baylor College Of Medicine - Houston
Quebec
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Montreal
California
- UCSF Birthmarks and Vascular Center - San Francisco
Colorado
- Childrens Hospital Colorado - Aurora
Missouri
- Washington Univ School Of Medicine - St Louis
New York
- Fink Childrens Ambulatory Care Ctr - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2021-04-19 |
| Est. Completion | 2031-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04589650
The ClinicalTrials.gov registry entry for NCT04589650 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 141-participant average among 3 other PIK3CA-related Overgrowth Spectrum (PROS) trials with a reported enrollment target (46% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PIK3CA-related Overgrowth Spectrum (PROS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04589650 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT04589650 about?
NCT04589650 is a clinical study titled "Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum". This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension periods to assess the efficacy, safety and pharmacokinetics (PK) of alpelisib in pediatric and adult patients with PIK3CA-related overgrowth spect...
What is the current status of trial NCT04589650?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2021-04-19. Estimated completion is 2031-01-09.
What conditions does trial NCT04589650 study?
This clinical trial studies the following conditions: PIK3CA-related Overgrowth Spectrum (PROS).
What interventions are being tested in trial NCT04589650?
The interventions under investigation include: Placebo (DRUG), Alpelisib (DRUG).
Who is sponsoring clinical trial NCT04589650?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04589650 being conducted?
This trial has 20 study locations across California, Colorado, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PIK3CA-related Overgrowth Spectrum (PROS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
RECRUITING · Phase 2
-
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
RECRUITING · Phase 2
-
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.